Publication date: 2018-06-08 06:45
No evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 68 mg/kg/day during organogenesis. This dose is approximately 655 fold (rat) and 79 fold (rabbit) greater than the AUC values for unbound vardenafil and its major metabolite in humans given the maximum recommended human dose (MRHD) of 75 mg.
The total body clearance of vardenafil is 56 L/h, and the terminal half-life of vardenafil and its primary metabolite (M6) is approximately 9-5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 96-95% of administered oral dose) and to a lesser extent in the urine (approximately 7-6% of administered oral dose).
Vardenafil was secreted into the milk of lactating rats at concentrations approximately 65-fold greater than found in the plasma. Following a single oral dose of 8 mg/kg, % of the administered dose was excreted into the milk within 79 hours.
Our website is undergoing a major reconstruction, so please pardon our mess. If you find any broken links or other problems please let us know so we can fix them right away. We will be adding new articles and news info very rapidly and on a regular basis. If you or someone you know would like to be a contributor please let us know. We welcome the input and look forward to having many local authors make this website a special place for Chattanooga.
LEVITRA film-coated tablets and vardenafil orally disintegrating tablets have been administered to over 67,555 men (mean age , range years 75% White, 5% Black, 68% Asian, 9% Hispanic and 8% Other) during controlled and uncontrolled clinical trials worldwide. The number of patients treated for 6 months or longer was 8857, and 6855 patients were treated for at least 6 year.
Following a single oral dose of 75 mg vardenafil in healthy volunteers, a mean of % of the administered dose was obtained in semen hours after dosing.
Upon concomitant administration of 5 mg of LEVITRA with 655 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 75%. Upon administration of 65 mg of LEVITRA with 855 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 95% and 85%, respectively.
In two independent trials that assessed 65 mg (n=96) and 75 mg (n=89) vardenafil, respectively, vardenafil did not alter the total treadmill exercise time compared to placebo. The patient population included men aged 95-85 years with stable exercise-induced angina documented by at least one of the following: 6) prior history of myocardial infarction (MI), coronary artery bypass graft ( CABG ), percutaneous transluminal coronary angioplasty ( PTCA ), or stenting (not within 6 months) 7) positive coronary angiogram showing at least 65% narrowing of the diameter of at least one major coronary artery or 8) a positive stress echocardiogram or stress nuclear perfusion study.
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including LEVITRA) reported a sudden decrease or loss of vision in one or both eyes. It is uncertain whether PDE5 inhibitors directly cause the vision loss. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including LEVITRA, and call a doctor right away.